GuruFocus·Sep 22, 2026
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still OvervaluedOn September 22, 2026, Axogen Inc (AXGN) shares fell by 3.0%, closing at $44.54. The stock is currently trading within a 52-week range of $15.27 to $52.91.
AxoGen's Q2 2026 revenue growth of 23.1% YoY demonstrates strong commercial momentum, but the company remains unprofitable with a -3.1% operating margin. The recent $150M equity raise and debt reduction to $20.1M provide a solid liquidity buffer, yet the BLA t...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.12-1.2% vs $0.12 | $70M+3.9% vs $67M |
Q2 2026 Apr 28, 2026 | $0.07-41.7% vs $0.12 | $61M+6.2% vs $58M |
Q1 2026 Feb 24, 2026 | $0.07-21.2% vs $0.09 | $60M+1.5% vs $59M |
Q4 2025 Oct 29, 2025 | $0.12+33.3% vs $0.09 | $60M+0.3% vs $60M |
On September 22, 2026, Axogen Inc (AXGN) shares fell by 3.0%, closing at $44.54. The stock is currently trading within a 52-week range of $15.27 to $52.91.
Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.
Medical-device stocks Cooper Companies Inc (NASDAQ:COO) and Axogen Inc (NASDAQ:AXGN) are both sharply lower following separate company developments, and options traders are chiming in.
Axogen, Inc. (AXGN) M&A Call Transcript
Benchmark AXGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AxoGen, Inc. (AXGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.39 | $2.01B | -109.97 | 20.21% | -6.97% | -13.49% | — | |
| $1.14 | $51M | -1.37 | 15.84% | -51.53% | — | — | |
| $14.94 | $1.73B | -12.25 | 8.28% | -21.25% | -44% | — | |
| $0.35 | $49.41M | 11.74 | 14.21% | -10.17% | -23.45% | — | |
| $4.59 | $669.04M | 14.34 | 19.99% | 1.76% | 2.61% | — | |
| $19.10 | $255.61M | -25.13 | -5.91% | -3.14% | -2.7% | — |
AxoGen, Inc. (AXGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AxoGen, Inc. (AXGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 23, 2026·SEC
Apr 28, 2026·SEC
Get notified when AXGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AxoGen, Inc. (AXGN) stock FAQ — growth, dividends, profitability & financials explained
AxoGen, Inc. (AXGN) reported $251.2M in revenue for fiscal year 2025. This represents a 1817% increase from $13.1M in 1996.
AxoGen, Inc. (AXGN) grew revenue by 20.2% over the past year. This is strong growth.
AxoGen, Inc. (AXGN) reported a net loss of $33.5M for fiscal year 2025.
AxoGen, Inc. (AXGN) has a return on equity (ROE) of -13.5%. Negative ROE indicates the company is unprofitable.
AxoGen, Inc. (AXGN) generated $2.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
